phgenomicsФармакогенетика и фармакогеномикаPharmacogenetics and Pharmacogenomics2588-05272686-8849LLC "Izdatelstvo OKI"10.37489/2588-0527-2025-1-9-16BNQBGPphgenomics-320Research ArticleФАРМАКОГЕНЕТИЧЕСКИЕ ИССЛЕДОВАНИЯPHARMACOGENETICS STUDYПолиморфные варианты генов SLC6A4 И TPH1 как предикторы эффективности и безопасности сертралина у больных со смешанным тревожно-депрессивным расстройством: пилотное исследованиеPolymorphic variants of SLC6A4 and TPH1 genes as predictors of sertraline efficacy and safety in patients with mixed anxiety-depressive disorder: a pilot studyhttps://orcid.org/0000-0003-0254-3917ГарееваА. Э.GareevaA. E.

Анна Эмировна Гареева, к. м. н., д. б. н., доцент, в. н. с., профессор

Институт биохимии и генетики; лаборатория молекулярной генетики человека; кафедра наркологии; лаборатория перспективных медицинских проектов

Уфа; Москва; Кемерово

Anna E. Gareeva, PhD, Cand. Sci. (Med), Dr. Sci. (Biology),Associate Professor, Leading Researcher, Professor

Laboratory of Human Molecular Genetics; Department of Narcology; Laboratory of Advanced Medical Projects

Ufa; Moscow; Kemerovo

annagareeva@yandex.ruhttps://orcid.org/0000-0001-5116-0790БородинаЛ. С.BorodinaL. S.

Лирида Сагитовна Бородина, врач-психиатр-нарколог

Уфа

Lirida S. Borodina, psychiatrist-narcologist

Ufa

slice92@yandex.ruhttps://orcid.org/0009-0007-2136-2931МихайловаЕ. Г.MikhailovaE. G.

Елена Геннадиевна Михайлова, врач-психиатр-нарколог, заведующая отделением

Уфа

Elena G. Mikhailova, psychiatrist-narcologist, head of department

Ufa

mih_elena75@mail.ruhttps://orcid.org/0000-0002-5198-6637ПоздняковС. А.PozdnyakovS. A.

Сергей Александрович Поздняков, младший научный сотрудник

Москва

Sergei A. Pozdniakov, Junior Researcher

Moscow

segeus@gmail.comhttps://orcid.org/0000-0001-5241-6073ТимербулатовИ. Ф.TimerbulatovI. F.

Ильгиз Фаритович Тимербулатов, д. м. н., доцент, главный врач, заведующий кафедрой, профессор, профессор кафедры

кафедра наркологии; кафедра психотерапии; НОИ клинической медицины им. Н.А. Семашко; лечебный факультет;  кафедра психиатрии, наркологии и психотерапии

Москва

Ilgiz F. Timerbulatov, PhD, Dr. Sci. (Med.), Associate Professor, Chief Physician, Head of the Department, Professor, Professor of the Department

Department of Narcology; Department of Psychotherapy; Scientific and Educational Institute of Clinical Medicine named NA Semashko; Faculty of Medicine; Department of Psychiatry, Narcology and Psychotherapy

Moscow

iftdoc@mail.ruФГБНУ «Уфимский федеральный исследовательский центр Российской академии наук»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования»; ФГБОУ ВО «Кемеровский государственный университет»РоссияUfa Federal Research Centre of the Russian Academy of Sciences; Russian Medical Academy of Continuous Professional Education; Kemerovo State UniversityRussian FederationГБУЗ «Республиканский клинический наркологический диспансер Министерства здравоохранения Республики Башкортостан»РоссияRepublican Clinical Narcological DispensaryRussian FederationГБУЗ «Московский научно-практический центр наркологии Департамента здравоохранения Москвы»РоссияMoscow Scientific and Practical Center for NarcologyRussian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования»; ГБУЗ МО «Центральная клиническая психиатрическая больница им. Ф.А. Усольцева»; ФГБОУ ВО «Российский университет медицины»РоссияRussian Medical Academy of Continuous Professional Education; Central Clinical Psychiatric Hospital named FA Usoltseva; Russian University of MedicineRussian Federation20253103202501916Copyright © Гареева А.Э., Бородина Л.С., Михайлова Е.Г., Поздняков С.А., Тимербулатов И.Ф., 20252025Гареева А.Э., Бородина Л.С., Михайлова Е.Г., Поздняков С.А., Тимербулатов И.Ф.Gareeva A.E., Borodina L.S., Mikhailova E.G., Pozdnyakov S.A., Timerbulatov I.F.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/320

В попытке улучшить эффективность антидепрессантов во всём мире проводятся фармакогенетические исследования полиморфных вариантов генов, участвующих в фармакодинамике селективных ингибиторов обратного захвата серотонина. В этом исследовании изучена взаимосвязь между полиморфными вариантами генов серотонинергической нейротрансмиссии rs4795541 гена SLC6A4 и rs1800532 гена TPH1 и ответом на терапию сертралином у пациентов со смешанным тревожно-депрессивным расстройством (F 41.2) из Республики Башкортостан. Пациенты принимали сертралин в течение 6 недель. Оценка эффективности терапии проводилась на исходном уровне и через 2, 4 и 6 недель с использованием стандартных психометрических шкал. Всем пациентам осуществлялся забор крови с последующим генотипированием. Статистическая обработка осуществлялась в программе SPSS Statistics v. 13.0. Было выявлено, что генотипы rs4795541*L/L и rs7997012*A/A можно рассматривать в качестве маркеров низкой эффективности терапии сертралином. Полученные результаты подтверждают гипотезу о влиянии полиморфизмов изученных генов на фармакогенетику сертралина и подчёркивают необходимость продолжения исследований.

In an attempt to improve the efficacy of antidepressants, pharmacogenetic studies of polymorphic variants of genes involved in the pharmacodynamics of selective serotonin reuptake inhibitors are being conducted worldwide. This study examined the relationship between polymorphic variants of the serotonergic neurotransmission genes rs4795541 of the SLC6A4 gene and rs1800532 of the TPH1 gene and the response to sertraline therapy in patients with mixed anxiety-depressive disorder (F 41.2) from the Republic of Bashkortostan. Patients took sertraline for 6 weeks. The effectiveness of therapy was assessed at baseline and after 2, 4 and 6 weeks using standard psychometric scales. All patients underwent blood sampling with subsequent genotyping. Statistical processing was performed in the SPSS Statistics v. 13.0 program. It was revealed that the rs4795541*L/L and rs7997012*A/A genotypes can be considered as markers of low efficacy of sertraline therapy. The obtained results confirm the hypothesis about the influence of polymorphisms of the studied genes on the pharmacogenetics of sertraline and emphasize the need for further research.

антидепрессантыфармакогенетикаселективные ингибиторы обратного захвата серотонинасертралинantidepressantspharmacogeneticsselective serotonin reuptake inhibitorssertralineИсследование выполнено при поддержке гранта Российского научного фонда № 24-25-00378, https://rscf.ru/project/24-25-00378/The study was supported by the Russian Science Foundation grant No. 24-25-00378, https://rscf.ru/ project/24-25-00378/ReferencesBotton MR, Yang Y, Scott ER, et al. Phased Haplotype Resolution of the SLC6A4 Promoter Using Long-Read Single Molecule Real-Time (SMRT) Sequencing. Genes (Basel). 2020 Nov 12;11(11):1333. doi: 10.3390/genes11111333.Botton MR, Yang Y, Scott ER, et al. Phased Haplotype Resolution of the SLC6A4 Promoter Using Long-Read Single Molecule Real-Time (SMRT) Sequencing. Genes (Basel). 2020 Nov 12;11(11):1333. doi: 10.3390/genes11111333.Zhu J, Klein-Fedyshin M, Stevenson JM. Serotonin Transporter Gene Polymorphisms and Selective Serotonin Reuptake Inhibitor Tolerability : Review of Pharmacogenetic Evidence. Pharmacotherapy. 2017 Sep;37(9):1089-1104. doi: 10.1002/phar.1978.Zhu J, Klein-Fedyshin M, Stevenson JM. Serotonin Transporter Gene Polymorphisms and Selective Serotonin Reuptake Inhibitor Tolerability : Review of Pharmacogenetic Evidence. Pharmacotherapy. 2017 Sep;37(9):1089-1104. doi: 10.1002/phar.1978.Stein K, Maruf AA, Müller DJ, et al. Serotonin Transporter Genetic Variation and Antidepressant Response and Tolerability : A Systematic Review and Meta-Analysis. J Pers Med. 2021 Dec 9;11(12):1334. doi: 10.3390/jpm11121334.Stein K, Maruf AA, Müller DJ, et al. Serotonin Transporter Genetic Variation and Antidepressant Response and Tolerability : A Systematic Review and Meta-Analysis. J Pers Med. 2021 Dec 9;11(12):1334. doi: 10.3390/jpm11121334.Brunoni AR, Carracedo A, Amigo OM, et al. Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial. Braz J Psychiatry. 2020 Apr;42(2):128-135. doi: 10.1590/1516-4446-2019-0620.Brunoni AR, Carracedo A, Amigo OM, et al. Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial. Braz J Psychiatry. 2020 Apr;42(2):128-135. doi: 10.1590/1516-4446-2019-0620.Porcelli S, Drago A, Fabbri C, et al. Pharmacogenetics of antidepressant response. J Psychiatry Neurosci. 2011 Mar;36(2):87-113. doi: 10.1503/jpn.100059.Porcelli S, Drago A, Fabbri C, et al. Pharmacogenetics of antidepressant response. J Psychiatry Neurosci. 2011 Mar;36(2):87-113. doi: 10.1503/jpn.100059.Zastrozhin MS, Grishina EA, Denisenko NP, et al. Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. Pharmgenomics Pers Med. 2018 Jun 29;11:113-119. doi: 10.2147/PGPM.S160763.Zastrozhin MS, Grishina EA, Denisenko NP, et al. Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. Pharmgenomics Pers Med. 2018 Jun 29;11:113-119. doi: 10.2147/PGPM.S160763.Serretti A, Cusin C, Rossini D, et al. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am J Med Genet B Neuropsychiatr Genet. 2004 Aug 15;129B(1):36-40. doi: 10.1002/ajmg.b.30027.Serretti A, Cusin C, Rossini D, et al. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am J Med Genet B Neuropsychiatr Genet. 2004 Aug 15;129B(1):36-40. doi: 10.1002/ajmg.b.30027.Ham BJ, Lee BC, Paik JW, et al. Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):104-7. doi: 10.1016/j.pnpbp.2006.08.001.Ham BJ, Lee BC, Paik JW, et al. Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):104-7. doi: 10.1016/j.pnpbp.2006.08.001.Secher A, Bukh J, Bock C, et al. Antidepressive-drug-induced bodyweight gain is associated with polymorphisms in genes coding for COMT and TPH1. Int Clin Psychopharmacol. 2009 Jul;24(4):199-203. doi: 10.1097/YIC.0b013e32832d6be2.Secher A, Bukh J, Bock C, et al. Antidepressive-drug-induced bodyweight gain is associated with polymorphisms in genes coding for COMT and TPH1. Int Clin Psychopharmacol. 2009 Jul;24(4):199-203. doi: 10.1097/YIC.0b013e32832d6be2.Serretti A, Zanardi R, Cusin C, et al. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur Neuropsychopharmacol. 2001 Oct;11(5):375-80. doi: 10.1016/s0924-977x(01)00113-4.Serretti A, Zanardi R, Cusin C, et al. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur Neuropsychopharmacol. 2001 Oct;11(5):375-80. doi: 10.1016/s0924-977x(01)00113-4.Arias B, Fabbri C, Gressier F, et al. TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression. Neuropsychobiology. 2013;67(1):41-7. doi: 10.1159/000343388.Arias B, Fabbri C, Gressier F, et al. TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression. Neuropsychobiology. 2013;67(1):41-7. doi: 10.1159/000343388.Calabrò M, Fabbri C, Crisafulli C, et al. The serotonin transporter and the activity regulated cytoskeleton-associated protein genes in antidepressant response and resistance: 5-HTTLPR and other variants. Hum Psychopharmacol. 2018 Nov;33(6):e2682. doi: 10.1002/hup.2682.Calabrò M, Fabbri C, Crisafulli C, et al. The serotonin transporter and the activity regulated cytoskeleton-associated protein genes in antidepressant response and resistance: 5-HTTLPR and other variants. Hum Psychopharmacol. 2018 Nov;33(6):e2682. doi: 10.1002/hup.2682.Huezo-Diaz P, Uher R, Smith R, et al. Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry. 2009 Jul;195(1):30-8. doi: 10.1192/bjp.bp.108.062521.Huezo-Diaz P, Uher R, Smith R, et al. Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry. 2009 Jul;195(1):30-8. doi: 10.1192/bjp.bp.108.062521.Smeraldi E, Zanardi R, Benedetti F, et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998 Nov;3(6):508-11. doi: 10.1038/sj.mp.4000425.Smeraldi E, Zanardi R, Benedetti F, et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998 Nov;3(6):508-11. doi: 10.1038/sj.mp.4000425.Zanardi R, Benedetti F, Di Bella D, et al. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol. 2000 Feb;20(1):105-7. doi: 10.1097/00004714-200002000-00021.Zanardi R, Benedetti F, Di Bella D, et al. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol. 2000 Feb;20(1):105-7. doi: 10.1097/00004714-200002000-00021.Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007 Mar;12(3):247-57. doi: 10.1038/sj.mp.4001926.Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007 Mar;12(3):247-57. doi: 10.1038/sj.mp.4001926.Wilkie MJ, Smith G, Day RK, et al. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J. 2009 Feb;9(1):61-70. doi: 10.1038/sj.tpj.6500491.Wilkie MJ, Smith G, Day RK, et al. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J. 2009 Feb;9(1):61-70. doi: 10.1038/sj.tpj.6500491.Poland RE, Lesser IM, Wan YJ, et al. Response to citalopram is not associated with SLC6A4 genotype in African-Americans and Caucasians with major depression. Life Sci. 2013 May 30;92(20-21):967-70. doi: 10.1016/j.lfs.2013.03.009.Poland RE, Lesser IM, Wan YJ, et al. Response to citalopram is not associated with SLC6A4 genotype in African-Americans and Caucasians with major depression. Life Sci. 2013 May 30;92(20-21):967-70. doi: 10.1016/j.lfs.2013.03.009.Hu XZ, Rush AJ, Charney D, et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry. 2007 Jul;64(7):783-92. doi: 10.1001/archpsyc.64.7.783.Hu XZ, Rush AJ, Charney D, et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry. 2007 Jul;64(7):783-92. doi: 10.1001/archpsyc.64.7.783.Smits KM, Smits LJ, Schouten JS, et al. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry. 2004 May;9(5):433-41. doi: 10.1038/sj.mp.4001488.Smits KM, Smits LJ, Schouten JS, et al. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry. 2004 May;9(5):433-41. doi: 10.1038/sj.mp.4001488.Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol. 2012 Apr;22(4):239-58. doi: 10.1016/j.euroneuro.2011.10.003.Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol. 2012 Apr;22(4):239-58. doi: 10.1016/j.euroneuro.2011.10.003.

The authors declare that there are no conflicts of interest present.